NASDAQ:ASND Ascendis Pharma A/S Q2 2026 Earnings Report $255.41 +5.56 (+2.23%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$255.93 +0.52 (+0.20%) As of 08/7/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ascendis Pharma A/S EPS ResultsActual EPSN/AConsensus EPS $1.71Beat/MissN/AOne Year Ago EPSN/AAscendis Pharma A/S Revenue ResultsActual RevenueN/AExpected Revenue$376.75 millionBeat/MissN/AYoY Revenue GrowthN/AAscendis Pharma A/S Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateThursday, August 13, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Ascendis Pharma A/S Earnings HeadlinesAscendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of "Buy" by AnalystsAugust 7 at 2:15 AM | americanbankingnews.comAscendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush SaysAugust 6 at 12:14 AM | finance.yahoo.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026August 6 at 12:14 AM | finance.yahoo.comAscendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.August 6 at 9:12 AM | finance.yahoo.comAscendis Pharma Expands Yorvipath Into Adolescents, Raising Long-Term Growth HopesJuly 28, 2026 | tipranks.comSee More Ascendis Pharma A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email. Email Address About Ascendis Pharma A/SAscendis Pharma A/S (NASDAQ:ASND) is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia. The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S. Food and Drug Administration for the treatment of pediatric growth hormone deficiency. By transiently conjugating active hormone to a carrier molecule, the TransCon platform allows controlled release of the therapeutic agent over time, reducing injection frequency and helping to maintain more consistent drug exposure. Beyond growth hormone deficiency, Ascendis Pharma is advancing a pipeline of product candidates aimed at other rare endocrine disorders. TransCon parathyroid hormone (PTH) is in clinical development for hypoparathyroidism and has demonstrated positive proof‐of‐concept data. The company is also investigating TransCon CNP for the treatment of achondroplasia, a form of dwarfism, and pursuing additional indications in both endocrine and broader metabolic diseases. Ascendis Pharma’s management team brings together experienced professionals in drug development, regulatory affairs and commercial strategy. The company continues to expand its global footprint through strategic collaborations and partnerships, with the goal of delivering transformative therapies to patients with underserved conditions.View Ascendis Pharma A/S ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in FocusDatadog’s Drop Says More About Expectations Than EarningsD-Wave's Quantum Breakthrough Couldn't Save QBTS From a Sell-OffBuy the Dip or Run: 3 Software Stocks Down 50% Face Their Moment of TruthSolventum Nears Inflection Point As It Begins to Unlock ValueBoeing's Comeback Is Building Momentum—Is It Real?Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
